Clinical trials: Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease, Hypercapnic Respiratory Failure
Validation of Chinese SRI Questionnaire
Assessment of health-related quality of life in COPD patients with severe chronic respiratory failure requires appropriate and highly specific measurement tools.
- Trial name
- VCSRI (NCT02240225)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
COPD
NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients
The goal of this observational study is to measure improvement in health related quality of life in moderate to severe COPD patients treated with Trimbow inhalation powder.
- Trial name
- RESPONSE (NCT05743608)
- Where
- 39 sites in Hungary
- Volunteers
- 1,336 people
- Sponsor
- Chiesi Hungary Ltd.
COPD
Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure
Chronic Obstructive Pulmonary Disease (COPD) is a disease that produces a high rate of social and economic health mortality and morbidity not only in our country but in the international field.
- Trial name
- EMERALD2 (NCT05506865)
- Testing
- Indacaterol, Tiotropium
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- National Institute of Respiratory Diseases, Mexico
Chronic Obstructive Pulmonary Disease
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum.
- Trial name
- DACOTA (NCT01285167)
- Testing
- Daxas
- Where
- 605 sites in Germany
- Volunteers
- 3,645 people
- Sponsor
- AstraZeneca
COPD
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic…
- Trial name
- GOLDEN-2 (NCT01706536)
- Testing
- EP-101 12.5 mcg, EP-101 25 mcg, EP-101 50 mcg
- Where
- 26 sites in United States
- Volunteers
- 275 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
- Trial name
- NCT05573464
- Testing
- BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
- Where
- 91 sites in United States, Argentina and 7 more
- Volunteers
- 559 people
- Sponsor
- AstraZeneca
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- CIRRUS (NCT01233232)
- Testing
- AZD5069 50mg, AZD5069 80mg
- Where
- 8 sites in Bulgaria, Germany and 2 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Anxiety, COPD
Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Anxiety and depression are common in patients with severe chronic obstructive pulmonary disease (COPD). Frequently exacerbation's of breathlessness are associated with panic/fear and indeed this may be the main cause for the for…
- Trial name
- NCT01522092
- Testing
- escitalopram
- Where
- United Kingdom
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Asthma, Asthma Chronic
Improving the Quality of Care for Asthma Patients at Risk of Exacerbations
The goal of this trial test two known effective asthma strategies. Treatment guidelines recommend combination therapy of inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA) inhaled medications.
- Conditions
- Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
- Trial name
- iCARE (NCT06596512)
- Testing
- PARTICS using a single ICS add on, MART
- Where
- 6 sites in United States
- Volunteers
- 4,100 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Disease, Chronic Obstructive
Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00430300
- Testing
- UK-432,097
- Where
- 22 sites in Australia, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Chronic, Non Malignant Pain
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
Two stage study looking at different titration schedules in patients with moderate to severe non-malignant chronic pain. Up to 80 patients at approximately 15 centers in the US to be enrolled.
- Trial name
- NCT00485225
- Testing
- EN3270
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Durect
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
Asthma, Chronic Inflammatory Diseases
Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics
Asthma is a chronic inflammatory disease, affecting up to 10 % of the general population in developed countries. Corticosteroids are necessary to control symptoms, but induce adverse events sometimes intolerable.
- Trial name
- EXPRESA (NCT00721097)
- Testing
- spirometry, and blood taken
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital
COPD
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
- Trial name
- NCT02465567
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg
- Where
- 741 sites in United States, Argentina and 24 more
- Volunteers
- 8,588 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second [FEV1]) over the full 24-h time period
- Trial name
- NCT00615030
- Testing
- Indacaterol, Salmeterol
- Where
- 7 sites in France, Germany and 1 more
- Volunteers
- 96 people
- Sponsor
- Novartis
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease, Pulmonary Rehabilitation
6-minute Stepper Test and Pulmonary Rehabilitation in Patients With Severe to Very Severe Chronicle Obstructive Pulmonary Disease
Chronicle obstructive pulmonary disease is a worldwide cause of mortality and morbidity. This systemic disease progressively leads to dyspnea, muscle wasting and exercise capacity impairment.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Rehabilitation, 6-minute Stepper Test
- Trial name
- 6STaR-2 (NCT04004689)
- Testing
- 2 times : 6-minute stepper test with a rest of 20min between each test.
- Where
- 4 sites in France
- Volunteers
- 80 people
- Sponsor
- ADIR Association
Emphysema or COPD
Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema
Patients with severe emphysema have limited options for treatment. Current treatments include lung transplant, lung volume reduction surgery or endobronchial lung volume reduction using valves or coils.
- Trial name
- EFFORT (NCT04520152)
- Testing
- FreeFlowMedical Lung Tensioning Device
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 14 people
- Sponsor
- University Medical Center Groningen
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca